|
MechanismPORCN inhibitors |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
This is a multi-center, open label, repeat dose, Phase 1 study consisting of a Dose Escalation Phase and a Dose Expansion Phase to evaluate safety, pharmacokinetics, and clinical activity.
100 Clinical Results associated with Guangzhou Curegenix Ltd.
0 Patents (Medical) associated with Guangzhou Curegenix Ltd.
100 Deals associated with Guangzhou Curegenix Ltd.
100 Translational Medicine associated with Guangzhou Curegenix Ltd.